Company news

Context Therapeutics Inc. news in 2025

Context Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

November 7, 2025

Context Therapeutics Reports Third Quarter 2025 Operating and Financial Results

November 5, 2025

Context Therapeutics Announces Poster Presentations at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting

October 6, 2025

Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

October 3, 2025

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

August 6, 2025

Context Therapeutics Announces CTIM-76 Trial in Progress Poster Presentation at 2025 ASCO Meeting

June 2, 2025

Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer

May 29, 2025

Context Therapeutics Reports First Quarter 2025 Operating and Financial Results

May 7, 2025

Context Therapeutics Announces Chief Medical Officer Transition

May 5, 2025

Context Therapeutics Presents Preclinical and Translational Data for CT-95, a Mesothelin Targeting T Cell Engager, at 2025 AACR Annual Meeting

April 30, 2025

Context Therapeutics Doses First Patient in Phase 1 Clinical Trial of CT-95

April 9, 2025

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025

March 26, 2025

Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026

March 25, 2025

Context Therapeutics Reports Full Year 2024 Operating and Financial Results

March 20, 2025

Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76

January 13, 2025

Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors

January 12, 2025

Decks in 2025